Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date

被引:43
作者
Boespflug, Amelie [1 ,2 ,3 ]
Caramel, Julie [3 ]
Dalle, Stephane [1 ,2 ,3 ]
Thomas, Luc
机构
[1] Hosp Civils Lyon, Dermatol Unit, Lyon, France
[2] Claude Bernard Lyon 1 Univ, Dept Med, Lyon, France
[3] Claude Bernard Lyon 1 Univ, Canc Res Ctr Lyon, CNRS 5286, INSERM 1052, Lyon, France
关键词
NRAS-mutant melanoma; targeted therapies; metastatic melanoma; clinical trials; ORAL MEK INHIBITOR; PHASE-II TRIAL; PROTEIN TRANSFERASE INHIBITOR; UNRESECTABLE STAGE-III; IB DOSE-ESCALATION; MUTANT MELANOMA; THERAPEUTIC TARGET; TRAMETINIB GSK1120212; CLINICAL ACTIVITY; 1ST-LINE THERAPY;
D O I
10.1177/1758834017708160
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The disease course of BRAF (v-raf murine sarcoma viral oncogene homolog B1)-mutant melanoma has been drastically improved by the arrival of targeted therapies. NRAS (neuroblastoma RAS viral oncogene homolog)-mutated melanoma represents 15-25% of all metastatic melanoma patients. It currently does not have an approved targeted therapy. Metastatic patients receive immune-based therapies as first-line treatments, then cytotoxic chemotherapy like carboplatin/paclitaxel (C/P), dacarbazine (DTIC) or temozolomide (TMZ) as a second-line treatment. We will review current preclinical and clinical developments in NRAS-mutated melanoma, and analyze ongoing clinical trials that are evaluating the benefit of different targeted and immune-based therapies, either tested as single agents or in combination, in NRAS-mutant melanoma.
引用
收藏
页码:481 / 492
页数:12
相关论文
共 103 条
[1]   A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors [J].
Adjei, Alex A. ;
LoRusso, Patricia ;
Ribas, Antoni ;
Sosman, Jeffrey A. ;
Pavlick, Anna ;
Dy, Grace K. ;
Zhou, Xiaofei ;
Gangolli, Esha ;
Kneissl, Michelle ;
Faucette, Stephanie ;
Neuwirth, Rachel ;
Bozon, Viviana .
INVESTIGATIONAL NEW DRUGS, 2017, 35 (01) :47-58
[2]   MEK and the inhibitors: from bench to bedside [J].
Akinleye, Akintunde ;
Furqan, Muhammad ;
Mukhi, Nikhil ;
Ravella, Pavan ;
Liu, Delong .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
[3]   The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial [J].
Algazi, A. P. ;
Cha, E. ;
Ortiz-Urda, S. M. ;
McCalmont, T. ;
Bastian, B. C. ;
Hwang, J. ;
Pampaloni, M. H. ;
Behr, S. ;
Chong, K. ;
Cortez, B. ;
Quiroz, A. ;
Coakley, F. ;
Liu, S. ;
Daud, A. I. .
BRITISH JOURNAL OF CANCER, 2015, 112 (08) :1326-1331
[4]   Developments in targeted therapy in melanoma [J].
Amann, V. C. ;
Ramelyte, E. ;
Thurneysen, S. ;
Pitocco, R. ;
Bentele-Jaberg, N. ;
Goldinger, S. M. ;
Dummer, R. ;
Mangana, J. .
EJSO, 2017, 43 (03) :581-593
[5]   Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases [J].
Amaravadi, Ravi K. ;
Schuchter, Lynn M. ;
McDermott, David F. ;
Kramer, Amy ;
Giles, Lydia ;
Gramlich, Kristi ;
Carberry, Mary ;
Troxel, Andrea B. ;
Letrero, Richard ;
Nathanson, Katherine L. ;
Atkins, Michael B. ;
O'Dwyer, Peter J. ;
Flaherty, Keith T. .
CLINICAL CANCER RESEARCH, 2009, 15 (24) :7711-7718
[6]  
[Anonymous], ONCOLOGY WILLISTON P
[7]  
Arance A, 2016, 13 INT C SMR ANN C B
[8]   Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma [J].
Atefi, Mohammad ;
Titz, Bjoern ;
Avramis, Earl ;
Ng, Charles ;
Wong, Deborah J. L. ;
Lassen, Amanda ;
Cerniglia, Michael ;
Escuin-Ordinas, Helena ;
Foulad, David ;
Comin-Anduix, Begonya ;
Graeber, Thomas G. ;
Ribas, Antoni .
MOLECULAR CANCER, 2015, 14
[9]   High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].
Atkins, MB ;
Lotze, MT ;
Dutcher, JP ;
Fisher, RI ;
Weiss, G ;
Margolin, K ;
Abrams, J ;
Sznol, M ;
Parkinson, D ;
Hawkins, M ;
Paradise, C ;
Kunkel, L ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116
[10]   Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients [J].
Baiter, Mirjam ;
Schuler, Gerold ;
Hartmann, Arndt ;
Schneider-Stock, Regine ;
Heinzerling, Lucie .
DERMATOLOGY, 2015, 231 (02) :127-133